HC Wainwright Reiterates Buy Rating for Scholar Rock (NASDAQ:SRRK)

Scholar Rock (NASDAQ:SRRK)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $58.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 24.62% from the company’s previous close.

SRRK has been the topic of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Wolfe Research assumed coverage on shares of Scholar Rock in a report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price on the stock. UBS Group assumed coverage on Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target on the stock. BMO Capital Markets reissued an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Friday, November 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $51.14.

Scholar Rock Stock Up 7.0%

NASDAQ:SRRK traded up $3.06 during trading hours on Tuesday, reaching $46.54. The company’s stock had a trading volume of 1,091,774 shares, compared to its average volume of 994,116. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. The company has a market cap of $4.75 billion, a price-to-earnings ratio of -14.77 and a beta of 0.70. Scholar Rock has a one year low of $22.71 and a one year high of $49.82. The business’s 50-day moving average is $45.32 and its 200-day moving average is $38.99.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). During the same period in the prior year, the business earned ($0.64) earnings per share. Equities research analysts predict that Scholar Rock will post -2.42 EPS for the current year.

Insider Transactions at Scholar Rock

In related news, insider Jing L. Marantz sold 4,157 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total value of $193,425.21. Following the completion of the transaction, the insider directly owned 126,012 shares in the company, valued at approximately $5,863,338.36. This represents a 3.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mo Qatanani sold 8,484 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total transaction of $399,341.88. Following the completion of the sale, the insider directly owned 98,445 shares in the company, valued at $4,633,806.15. This trade represents a 7.93% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 344,932 shares of company stock valued at $15,371,225. Company insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Institutional investors have recently added to or reduced their stakes in the stock. Three Seasons Wealth LLC grew its stake in shares of Scholar Rock by 2.1% in the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after purchasing an additional 222 shares during the period. IFP Advisors Inc grew its position in Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the period. Principal Financial Group Inc. raised its stake in Scholar Rock by 7.9% during the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock worth $231,000 after acquiring an additional 456 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after acquiring an additional 525 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of Scholar Rock by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock worth $2,209,000 after purchasing an additional 577 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).